Context Therapeutics Inc. (NASDAQ:CNTX) Position Reduced by Great Point Partners LLC

Great Point Partners LLC trimmed its holdings in shares of Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) by 6.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,934,982 shares of the company's stock after selling 484,373 shares during the period. Context Therapeutics comprises approximately 4.0% of Great Point Partners LLC's portfolio, making the stock its 9th largest position. Great Point Partners LLC owned about 9.25% of Context Therapeutics worth $13,593,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Renaissance Technologies LLC lifted its position in Context Therapeutics by 63.4% in the second quarter. Renaissance Technologies LLC now owns 65,200 shares of the company's stock valued at $131,000 after purchasing an additional 25,300 shares during the last quarter. Opaleye Management Inc. grew its holdings in Context Therapeutics by 13.7% in the 1st quarter. Opaleye Management Inc. now owns 1,108,357 shares of the company's stock worth $1,530,000 after acquiring an additional 133,357 shares during the last quarter. Ally Bridge Group NY LLC raised its stake in shares of Context Therapeutics by 159.8% during the second quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company's stock valued at $3,782,000 after acquiring an additional 1,160,281 shares during the last quarter. Affinity Asset Advisors LLC boosted its holdings in shares of Context Therapeutics by 392.4% during the second quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company's stock worth $3,246,000 after purchasing an additional 1,290,323 shares during the period. Finally, Nantahala Capital Management LLC bought a new stake in shares of Context Therapeutics in the second quarter worth about $3,881,000. Institutional investors own 14.03% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on CNTX shares. D. Boral Capital started coverage on Context Therapeutics in a research note on Monday. They set a "buy" rating and a $9.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $6.00 price objective on shares of Context Therapeutics in a research report on Monday, September 23rd. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Context Therapeutics currently has a consensus rating of "Buy" and an average price target of $6.80.

Context Therapeutics Stock Up 0.7 %

Shares of CNTX stock opened at $1.47 on Wednesday. The business's fifty day moving average is $1.97 and its 200 day moving average is $2.08. Context Therapeutics Inc. has a twelve month low of $0.77 and a twelve month high of $2.75.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.11). Analysts forecast that Context Therapeutics Inc. will post -0.51 EPS for the current fiscal year.

Context Therapeutics Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.

Want to see what other hedge funds are holding CNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Context Therapeutics Inc. (NASDAQ:CNTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.